Pathway Capital Management, LP Mersana Therapeutics, Inc. Transaction History
Pathway Capital Management, LP
- $107 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding MRSN
# of Institutions
128Shares Held
118MCall Options Held
68.1KPut Options Held
140K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$36.4 Million2.47% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$21.3 Million4.36% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$16.3 Million5.86% of portfolio
-
Black Rock Inc. New York, NY8.1MShares$15.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.27MShares$11.8 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $183M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...